Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.

ABSTRACT:

Background

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system and is one of the leading causes of disability in young adults. Cell therapy is emerging as a therapeutic strategy to promote repair and regeneration in patients with disability associated with progressive MS.

Methods

We conducted a phase I open-label clinical trial investigating the safety and tolerability of autologous bone marrow mesenchymal stem cell-derived neural progenitor (MSC-NP) treatment in 20 patients with progressive MS. MSC-NPs were administered intrathecally (IT) in three separate doses of up to 1 × 10⁷ cells per dose, spaced three months apart. The primary endpoint was to assess safety and tolerability of the treatment. Expanded disability s

SUBMITTER: Harris VK 

PROVIDER: S-EPMC5925446 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature